MIRA INFORM REPORT

 

 

Report No. :

344206

Report Date :

14.10.2015

 

IDENTIFICATION DETAILS

 

Name :

VIDORA FARMACEUTICA LTDA

 

 

Registered Office :

Rua Alberto Rangel,823 - Rubem Berta

 

 

Country :

Brazil

 

 

Financials (as on) :

31.12.2014

 

 

Date of Incorporation :

30.08.1966

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Manufacture of Drugs For Human Use.

 

 

No. of Employees :

82

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 200.000,00

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Brazil

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

BRAZIL - ECONOMIC OVERVIEW

 

Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly expanding middle class, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. Since 2008, Brazil became a net external creditor and all three of the major ratings agencies awarded investment grade status to its debt. After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. After reaching historic lows of 4.5% in early 2014, the unemployment rate remains low, but is rising. Brazil's traditionally high level of income inequality has declined for each of the last 15 years. GDP growth has slowed since 2011, due to several factors, including: overdependence on exports of raw commodities, low productivity, high operational costs, persistently high inflation, and low levels of investment. Brazil’s fiscal and current account balances have eroded during the past four years as the government attempted to boost economic growth through targeted tax cuts for industry and incentives to spur household consumption. After winning re-election in October 2014 by a historically narrow margin, President Dilma ROUSSEFF appointed a new economic team led by Finance Minister Joaquim LEVY, who introduced a fiscal austerity package intended to restore the primary account surplus to 1.2% of GDP and preserve the country’s investment-grade sovereign credit rating. Brazil seeks to strengthen its workforce and its economy over the long run by imposing local content and technology transfer requirements on foreign businesses, by investing in education through social programs such as Bolsa Familia and the Brazil Science Mobility Program, and by investing in research in the areas of space, nanotechnology, healthcare, and energy.

 

Source : CIA

 

Company name

 

VIDORA FARMACEUTICA LTDA

 

 

ADDRESSES

 

MAIN ADDRESS:

RUA ALBERTO RANGEL,823 - RUBEM BERTA

ZIP CODE/CITY:

91.180-840 -  PORTO ALEGRE/RS

 

 

PHONE:

51 3230-4086

FAX:

51 3230-4086

E-MAIL:

luciana.tomazine@cervosul.com.br

WEB SITE:

www.vidora.com.br

 

 

BRANCHES

 

NOT AVAILABLE.

 

 

LEGAL DATA

 

MAIN ACTIVITIES:

 

MANUFACTURE OF DRUGS FOR HUMAN USE.

 

LEGAL FORM:

LIMITED LIABILITY COMPANY

 

 

INCORPORATION DATE:

30/08/1966

REGISTER DATE:

30/08/1966

BALANCE SHEET FILING DATE:

31/12

TAX CONTRIBUTOR NUMBER(CNPJ):

92.762.277/0001-70

STATE REGISTER:

960.023.968

 

 

SHARE CAPITAL:

R$ 26.313.107,00

 

 

BOARD OF DIRECTORS

 

 

 

GENESIO CERVO

MANAGING PARTNER

 

AUTHORIZED USE OF SIGNATURE

 

THE MANAGING PARTNER IS AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY.

 

 

SHAREHOLDERS / PARTNERS

 

 

 

GENESIO CERVO

99,92%

GCPAR PARTICIPAÇÕES LTDA

0,08%

 

 

AFFILIATES / SUBSIDIARIES

 

 

A SCAN THROUGH OUTSIDE SOURCES SHOWED THE SUBJECT AND/OR DIRECTORS HAS/HAVE THE FOLLOWING UNCONFIRMED HOLDINGS:

 

 

 MBJP IMOVEIS LTDA

 

 JASPE EMPREENDIMENTO IMOBILIARIO LTDA - SPE

 

 VOGHA HIGIENE E BELEZA LTDA

 

 CERVOSUL DISTRIBUIDORA DE MEDICAMENTOS LTDA

 

 

 

COMPANY'S BACKGROUND

 

THE SUBJECT WAS ESTABLISHED ON AUGUST 30, 1966 AS LABORATORIOS KLEIN LTDA. TO BE ENGAGED IN THE SAID LINE OF BUSINESS. LATER IT ADOPTED THE ABOVE MENTIONED NAME AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL SCENE REPORTED HEREIN.

 

FURTHER DETAILS ARE SO FAR NOT KNOWN.

 

 

PUBLIC INFORMATION

 

NO DETRIMENTAL FILES WERE FOUND.

(RESEARCH DATE: 09/10/2015)

 

 

FINANCIAL INFORMATION

 

GENERAL BALANCE SHEETS AS OF 31/12/2014 AND 31/12/2013.

( FIGURES ARE IN REAIS ).

 

ASSETS

 

 

 

CURRENT:

31/12/2014

31/12/2013

 

 

 

 

 

CASH AND CASH EQUIVALENTS

79.737,50

88.728,73

 

CLIENTS

2.813.466,96

1.230.804,63

 

INVENTORY

4.158.030,84

2.691.349,57

 

ADVANCES

3.171.977,37

4.587.032,96

 

RECOVERABLE TAXES

1.455.554,16

315.331,90

 

OTHER

580.272,22

 

 

PREPAID EXPENSES

38.307,30

12.403,77

 

 

----------------

----------------

 

TOTAL CURRENT ASSETS

12.297.346,35

8.925.651,56

 

 

LONG-TERM RECEIVABLES:

 

 

 

 

 

 

 

JUDICIAL DEPOSITS

277.285,38

277.285,38

 

 

----------------

----------------

 

TOTAL LONG-TERM RECEIVABLES

277.285,38

277.285,38

 

 

FIXED ASSETS:

 

 

 

 

 

 

 

FIXED ASSETS

23.718.901,58

6.916.215,01

 

INTANGIBLE

1.269.633,14

632.732,72

 

 

----------------

----------------

 

TOTAL FIXED ASSETS

24.988.534,72

7.548.947,73

 

 

================

================

 

TOTAL ASSETS

37.563.166,45

16.751.884,67

 

 

LIABILITIES:

 

 

 

CURRENT:

31/12/2014

31/12/2013

 

 

 

 

 

SUPPLIERS

1.992.415,86

1.311.546,99

 

TAXES & CONTRIBUTIONS

550.944,30

536.511,43

 

SOCIAL OBLIGATIONS

310.561,61

207.336,21

 

LOANS AND FINANCING

667.722,33

 

 

 

----------------

----------------

 

TOTAL CURRENT LIABILITIES

3.521.644,10

2.055.394,63

 

 

LONG TERM LIABILITIES:

 

 

 

 

 

 

 

RELATED COMPANIES

 

19.192,98

 

LOANS AND FINANCING

22.745.551,57

-5.000,00

 

INSTALLMENTS TAXES PAYABLE

4.625.678,56

4.282.020,41

 

 

----------------

----------------

 

TOTAL LONG TERM LIABILITIES

27.371.230,13

4.296.213,39

 

 

NET EQUITY:

 

 

 

 

 

 

 

SHARE CAPITAL

26.313.108,14

26.313.108,14

 

CAPITAL RESERVES

89.340,60

89.340,60

 

OTHER COMPREHENSIVE INCOME

1.108.400,80

1.080.460,41

 

ACCRUED PROFIT (LOSS)

-20.840.557,32

-17.082.632,50

 

 

----------------

----------------

 

TOTAL NET EQUITY

6.670.292,22

10.400.276,65

 

 

================

================

 

TOTAL LIABILITIES

37.563.166,45

16.751.884,67

 

 

PROFIT AND LOSS ACCOUNTS AS OF 31/12/2014 AND 31/12/2013.

( FIGURES ARE IN REAIS ).

 

 

31/12/2014

31/12/2013

 

 

 

 

 

GROSS SALES

7.692.105,48

4.861.266,99

 

(-) TAXES ON SALES

1.697.839,68

1.050.671,92

 

 

----------------

----------------

 

NET SALES

5.994.265,80

3.810.595,07

 

(-) COST OF SOLD GOODS

4.677.455,07

2.853.606,85

 

 

----------------

----------------

 

GROSS PROFIT

1.316.810,73

956.988,22

 

OPERATING REVENUE (EXPENSE)

-4.335.439,30

-3.210.429,28

 

FINANCIAL REVENUE(EXPENSE)

-710.279,06

-1.328.784,98

 

 

----------------

----------------

 

OPERATIONAL PROFIT (LOSS)

-3.728.907,63

-3.582.226,04

 

 

----------------

----------------

 

NET PROFIT (LOSS)

-3.728.907,63

-3.582.226,04

 

 

MONTHLY SALES

 

  2015

 

 

 

---------------------

 

 

JANUARY

R$ 490.340,85

 

 

FEBRUARY

R$ 573.644,05

 

 

MARCH

R$ 1.131.617,81

 

 

APRIL

R$ 915.461,03

 

 

MAY

R$ 711.899,30

 

 

JUNE

R$ 615.016,54

 

 

JULY

R$ 670.728,16

 

 

AUGUST

R$ 590.535,36

 

 

SEPTEMBER

R$ 494.432,66

 

 

OCTOBER

 

 

 

NOVEMBER

 

 

 

DECEMBER

 

 

 

TOTAL

R$ 6.193.675,76

 

 

 

RATIOS:

31/12/2014

31/12/2013

 

 

QUICK RATIO

2,31

 

3,03

 

 

 

CURRENT RATIO

3,49

 

4,34

 

 

 

ACCOUNTS RECEIVABLE TURNOVER

2,13

TIMES

3,10

TIMES

 

 

DAYS' SALES IN RECEIVABLES

168,97

DAYS

116,28

DAYS

 

 

INVENTORY TURNOVER

1,12

TIMES

1,06

TIMES

 

 

ACCOUNTS PAYABLE PERIOD

153,35

DAYS

165,46

DAYS

 

 

RETURN ON ASSETS

,16

TIMES

,23

TIMES

 

 

SALES TURNOVER ON NET EQUITY

,90

TIMES

,37

TIMES

 

 

NET WORTH TIE-UP

3,56

 

,67

 

 

 

INDEBTEDNESS

4,63

 

,61

 

 

 

EQUITY RATIO

17,76

%

62,08

%

 

 

WORKING CAPITAL RATIO

249,19

%

334,25

%

 

 

GENERAL SOLVENCY

1,22

 

2,64

 

 

 

RETURN ON NET EQUITY

-55,90

%

-34,44

%

 

 

RETURN ON SALES (PROFIT MARGIN)

-62,21

%

-94,01

%

 

 

GROSS PROFIT MARGIN

21,97

%

25,11

%

 

 

OPERATIONAL RESULT

-62,21

%

-94,01

%

 

 

SALES TURNOVER ON LIABILITIES

1,70

TIMES

1,85

TIMES

 

 

FOREIGN CURRENCY ON ASSETS

 

 

 

 

 

 

FOREIGN CURRENCY ON LIABILITIES

 

 

 

 

 

 

 

 

EXCHANGE RATE

 

US$ 1,00 = R$ 3,73

 - OFFICIAL RATE ON 09/10/2015

US$ 1,00 = R$ 2,65

 - OFFICIAL RATE ON 31/12/2014

US$ 1,00 = R$ 2,34

 - OFFICIAL RATE ON 31/12/2013

 

 

COMMENTS ON THE FINANCIAL INFORMATION:

 

FOLLOWS ATTACHED WORKSHEET WITH MAIN FINANCIAL RATIOS.

 

THE FIGURES AVAILABLE SHOW AN UNBALANCED FINANCIAL STANDING. THE LEVEL OF INDEBTEDNESS IS VERY HIGH BUT IT IS NOTED HIGH LIQUIDITY RATIOS AND POSITIVE WORKING CAPITAL AMOUNT. IN ADDITION IT SHOWS GROWING SALES BUT POSTED STRONG NEGATIVE RESULTS DUE TO ITS HIGH EXPENSES.

 

 

REAL ESTATE

 

  NOT AVAILABLE

 

 

VEHICLES

 

   NOT AVAILABLE

 

 

MACHINES

 

 NOT AVAILABLE

INSURANCE

 

NOT AVAILABLE.

 

 

BANKING REFERENCES

 

NOT AVAILABLE.

 

 

 

REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS.

 

ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS NOT RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK"). DATE RESEARCHED OCTOBER 09, 2015.

 

 

ACTIVITIES COMMENTS

 

MANUFACTURE OF DRUGS FOR HUMAN USE.

 

 

IMPORT AND EXPORT

 

IMPORTS FROM:

NOT AVAILABLE.                    

 

EXPORTS TO:

NOT AVAILABLE.

 

 

MAIN CLIENTS

 

 

 

 

 

DOMESTIC CLIENTS:

 

 

NOT AVAILABLE.

 

 

 

 

STAFF

 

THE COMPANY HAS: 82 EMPLOYEE(S)

CONCEPT AND FULFILMENT

 

THE SUBJECT WAS ESTABLISHED IN 1966. SO FAR IT HAS A CLEAR TRADE HISTORY AND NORMAL PAYMENT BEHAVIOUR.

 

THE COMPANY HAS TRADE RELATIONS WITH SOME LOCAL SUPPLIERS BUT UP TO DATE ONLY SMALL PAYMENTS WERE REPORTED AND THE SUBJECT IS NOT SAID TO BE USER OF TRADE CREDIT FACILITIES.

 

 

MAIN SUPPLIERS

 

 

 

 

 

DOMESTIC SUPPLIERS:

 

 

ATACADAO DIST. COM. IND. LTDA

 

 

FRIGELAR COMERCIO E DISTRIBUIÇÃO S/A

 

 

NAT GEO COM. REPRES LTDA

 

 

 

 

PAYMENT HISTORY

 

7 SUPPLIERS REPORTED PAYMENTS:

   TOTAL AMOUNT:  R$ 33.017,00

 

AMOUNT OF INVOICES PAID: 22

TOTAL OF PROMPT PAYMENTS: 100%

HIGHEST INVOICE: R$ 3.649,00

HIGHEST CREDIT: R$ 3.649,00

 

 

FINAL OPINION

 

BASED ON THE GENERAL INFORMATION AVAILABLE IT IS BELIEVED THAT GOOD TRADE RELATIONS MAY BE ESTABLISHED. CREDIT FACILITIES MAY BE EXTENDED WITHIN TERMS AND AMOUNTS ADEQUATE TO THE COMPANY’S FINANCIAL STRENGTH.

 

DESPITE THE NEGATIVE RESULTS A CREDIT LIMIT OF USD 200.000,00 MAY BE CONSIDERED. FOR HIGHER AMOUNTS IT IS RECOMMENDED SOME CAUTION.

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.65.02

UK Pound

1

Rs.99.89

Euro

1

Rs.73.92

 

INFORMATION DETAILS

 

Analysis Done by :

HNA

 

 

Report Prepared by :

TRU

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.